Comparing Human Albumin Versus Hydroxyethylstarch in Renal Transplant Recipients

Anesthesia Morbidity Clinical Trial

Official title:

Plasma Volume Expansion for Optimum Renal Transplant Surgery: Albumin Versus Starch

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03306914
• Other study ID #: Albumin versus starch
• Status: Completed
• Phase: N/A
• Start date: October 15, 2017
• Est. completion date: February 1, 2019

Study information

• Verified date: January 2020
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study we try to review the possible effects when using modern hydroxyethylstarch solutions 6 % versus albumin 5% during living donor renal transplantation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: February 1, 2019
• Est. primary completion date: February 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• end stage renal disease, for living donor renal transplantation

Exclusion Criteria:

• severe cardiac or hepatic dysfunction, re-transplantation, coagulopathy

Related Conditions & MeSH terms

• Anesthesia Morbidity

Intervention

Other:
• Albumin resuscitation
Albumin 5% is used as the intra-operative colloid
• Hydroxyethylstarch resuscitation
Hydroxyethyl starch 6% is used as the intra-operative colloid

Drug:
• Albumin 5%
Infusion of Albumin 5% intra-operatively
• Hydroxyethylstarch 6%
Infusion of Hydroxyethylstarch 6% intra-operatively

Locations

Country	Name	City	State
Egypt	Cairo University	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of complications	Increased creatinine and/or need for dialysis	7 days